Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
seasonal influenza hemagglutinin vaccine
- Development stage
- Unknown
- Lead developer
- Daiichi Sankyo
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Subcutaneous, Intramuscular
01
Overview
The seasonal influenza hemagglutinin (HA) vaccine, developed and manufactured by Daiichi Sankyo, is an inactivated, quadrivalent split-virion vaccine indicated for the prevention of influenza. It is formulated annually to match the viral strains recommended by the World Health Organization (WHO) and the Japanese Ministry of Health, Labour and Welfare. The vaccine contains purified hemagglutinin antigens from two influenza A subtypes (H1N1 and H3N2) and two influenza B lineages (Victoria and Yamagata). Its mechanism of action involves stimulating the immune system to produce HA-specific neutralizing antibodies. These antibodies bind to the viral hemagglutinin protein, preventing the virus from attaching to sialic acid receptors on host respiratory epithelial cells, thereby neutralizing the virus and preventing infection. In the Japanese market, it is typically administered via subcutaneous or intramuscular injection.
- Brand names
- Influenza HA Vaccine Daiichi Sankyo
- Other names
- Influenza HA VaccineFlu HA VaccineSeasonal Influenza HA VaccineInactivated Influenza HA Vaccine
02
Targets
HA (Hemagglutinin)
Beyond the preview
Go deeper on seasonal influenza hemagglutinin vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on seasonal influenza hemagglutinin vaccine.